Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.

The ability of tricyclic antidepressants (TCAs) to inhibit phenytoin p-hydroxylation was evaluated in vitro by incubation studies of human liver microsomes and cDNA-expressed cytochrome p450s (p450s). The TCAs tested were amitriptyline, imipramine, nortriptyline, and desipramine. Amitriptyline and imipramine strongly and competitively inhibited phenytoin p-hydroxylation in microsomal incubations (estimated K(i) values of 5.2 and 15.5 micro M, respectively). In contrast, nortriptyline and desipramine produced only weak inhibition. In the incubation study using cDNA-expressed P450s, both CYP2C9 and CYP2C19 catalyzed phenytoin p-hydroxylation, whereas TCAs inhibited only the CYP2C19 pathway. All of the TCAs tested inhibited CYP2D6-catalyzed dextromethorphan-O-demethylation competitively, with estimated K(i) values of 31.0, 28.6, 7.9, and 12.5 micro M, respectively. The tertiary amine TCAs, amitriptyline and imipramine, also inhibited CYP2C19-catalyzed S-mephenytoin 4'-hydroxylation (estimated K(i) of 37.7 and 56.8 micro M, respectively). The secondary amine TCAs, nortriptyline and desipramine, however, showed minimal inhibition of CYP2C19 (estimated IC(50) of 600 and 685 micro M, respectively). None of the TCAs tested produced remarkable inhibition of any other p450 isoforms. These results suggest that TCAs inhibit both CYP2D6 and CYP2C19 and that the interaction between TCAs and phenytoin involves inhibition of CYP2C19-catalyzed phenytoin p-hydroxylation.

[1]  R. Levy Cytochrome P450 Isozymes and Antiepileptic Drug Interactions , 1995, Epilepsia.

[2]  E. Tanaka,et al.  Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system , 1999, Journal of clinical pharmacy and therapeutics.

[3]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[4]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[5]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[6]  A. Richens,et al.  Effect of Drug Therapy on the Metabolism of Phenytoin , 1975 .

[7]  T. Andersson,et al.  A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients , 1990, Therapeutic drug monitoring.

[8]  I. Niopas,et al.  Further insight into the stereoselective interaction between warfarin and cimetidine in man. , 1991, British journal of clinical pharmacology.

[9]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[10]  K. Chiba,et al.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. , 1994, British journal of clinical pharmacology.

[11]  R. Tukey,et al.  Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. , 1993, The Journal of pharmacology and experimental therapeutics.

[12]  L. Ereshefsky,et al.  Antidepressant Drug Interactions and the Cytochrome P450 System , 1995, Clinical pharmacokinetics.

[13]  E. Yukawa,et al.  The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics , 1998, Epilepsia.

[14]  N. Weiss Definition of screening status in case-control studies of the efficacy of endoscopy. , 1996, Archives of internal medicine.

[15]  D. Shen,et al.  Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J. Y. Park,et al.  Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. , 2001, British journal of clinical pharmacology.

[17]  J. Rindone,et al.  Phenytoin toxicity associated with ticlopidine administration. , 1996, Archives of internal medicine.

[18]  H. Yamazaki,et al.  Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[19]  H. Gutfreund,et al.  Enzyme kinetics , 1975, Nature.

[20]  R. Milne,et al.  Pharmacokinetic Drug Interactions with Phenytoin (Part I) , 1990 .

[21]  Karthik Venkatakrishnan,et al.  Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine , 2001, European Journal of Clinical Pharmacology.

[22]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[23]  G. Jones,et al.  Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. , 1997, Journal of forensic sciences.

[24]  R. Gieschke,et al.  Interaction studies with moclobemide , 1990, Acta psychiatrica Scandinavica. Supplementum.

[25]  M. Barry,et al.  Enzyme induction and inhibition. , 1990, Pharmacology & therapeutics.

[26]  E. Perucca,et al.  Interaction between phenytoin and imipramine. , 1977, British journal of clinical pharmacology.

[27]  J S Harmatz,et al.  Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. , 2003, British journal of clinical pharmacology.

[28]  G. Smith,et al.  Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[30]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[31]  D. Flockhart,et al.  Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[32]  A. Cicolin,et al.  Interactions Between Anticonvulsant and Psychoactive Drugs , 1999, Epilepsia.

[33]  P. Baumann,et al.  Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or Amitriptyline , 1992, Therapeutic drug monitoring.

[34]  P. Bechtel,et al.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. , 1989, British journal of clinical pharmacology.

[35]  P. Beaune,et al.  Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.

[36]  Q. Yue,et al.  Different effects of inhibitors on the O - and N -demethylation of codeine in human liver microsomes , 1997, European Journal of Clinical Pharmacology.

[37]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.